68.14
-2.58(-3.65%)
Currency In USD
| Previous Close | 70.72 |
| Open | 70.63 |
| Day High | 70.85 |
| Day Low | 67.43 |
| 52-Week High | 84.94 |
| 52-Week Low | 28.33 |
| Volume | 5.07M |
| Average Volume | 2.6M |
| Market Cap | 13.13B |
| PE | -16.19 |
| EPS | -4.21 |
| Moving Average 50 Days | 75.42 |
| Moving Average 200 Days | 55.87 |
| Change | -2.58 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $2,473.32 as of February 21, 2026 at a share price of $68.14. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $1,037.61 as of February 21, 2026 at a share price of $68.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
GlobeNewswire Inc.
Feb 17, 2026 12:30 PM GMT
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
GlobeNewswire Inc.
Feb 12, 2026 12:30 PM GMT
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jan 27, 2026 10:10 PM GMT
PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected relea